Zhao Liling, Director of the party member and Dalian Municipal Government Offices of the Democratic Progressive Party, writes about social conditions and public opinion. In recent years, with the rising average height of teenagers and children and the improvement of people's aesthetic requirements in job hunting, marriage and mate selection, more and more parents are worried about their children's "dwarfism" and try their best to "encourage" them. Some private medical institutions and related product companies have grasped the parents' "height anxiety" psychology. Ignoring the health risks such as endocrine disorders and scoliosis that may be caused by the abuse of growth hormone, speculating the so-called "booster needle" effect, and even injecting "booster needle" for teenagers and children "beyond the instructions" is worthy of sufficient vigilance.
"In violation of scientific laws, the abuse of growth hormone can not only make high profits from it, but also an important reason is that the current diagnosis and treatment norms of growth hormone are not perfect." Zhao Liling said that the National Health and Family Planning Commission has published clinical pathways since 2009 and has been constantly revising them. Among them, the Clinical Pathway of Dwarf Patients (20 19 edition) clearly pointed out that "those diagnosed with growth hormone deficiency should be treated with growth hormone", but it did not explain more about the treatment scope of growth hormone. In this way, the main producers of growth hormone have become "athletes" and "referees" in the formulation of growth hormone diagnosis and treatment norms, laying a hidden danger for abuse.
In this regard, Zhao Liling made three suggestions:
1
"Growth hormone" will be included in the national centralized procurement catalogue, and growth hormone drugs will be included in the scope of medical insurance supervision through centralized procurement to prevent growth hormone from being abused among children. At the same time, through strict supervision, regulate the use of growth hormone, and prevent some medical institutions from using growth hormone beyond the specification and scope of instructions.
2
It is suggested that National Health Commission and other relevant departments should make clear the applicable treatment scope of growth hormone and explain it as soon as possible, so as to ensure the standardization and professionalism of pediatricians in diagnosis, evaluation, treatment and follow-up monitoring.
three
The original text was published in the 6th edition of People's Political Consultative Conference Newspaper on May 9, 2022.
Author: Wang Lu